CONMED (CNMD) reported Q2 adjusted earnings late Wednesday of $1.38 per diluted share, up from $1.15 a year earlier.
Analysts polled by FactSet expected $1.11.
Revenue in the three months ended June 30 rose to $343.5 million from $342.3 million a year earlier.
Analysts surveyed by FactSet expected $337.6 million.
The company raised its full-year adjusted EPS guidance to $4.48 to $4.60 from its prior outlook of $4.30 to $4.45 and updated its revenue guidance to $1.358 billion to $1.373 billion from $1.350 billion to $1.375 billion.
Analysts expect EPS of $4.52 on revenue of $1.36 billion.
Shares of the company were up 6.5% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.